Lung Cancer Trial, Recruiting NCT03785574 Sponsor: Women's Hospital School Of Medicine Zhejiang University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT03785574
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a hydatidiform mole (an abnormal growth that forms in the uterus instead of a normal pregnancy), confirmed by laboratory or tissue testing
  • People who have small spots or nodules found on a lung scan (CT scan), where it cannot be ruled out that these spots may have spread from the mole
  • People whose hormone levels (a pregnancy-related hormone called hCG) do not yet meet the official medical standards for diagnosing a cancerous form of the condition
  • People who are willing to follow the study plan and attend regular check-up appointments
  • People who agree to sign a consent form before taking part

Who may not be able to join:

  • People who had lung nodules or spots on their lungs before their current diagnosis
  • People whose lung scan results clearly suggest the nodules are caused by another condition, such as tuberculosis or pneumonia
  • People who have already had their uterus surgically removed as a preventive measure, or who have already received chemotherapy
  • People who have already been diagnosed with a cancerous form of the condition (gestational trophoblastic neoplasia) before or at the time of joining the trial
  • People who have a disease that affects the immune system, or who are taking medications that suppress the immune system
  • People who are currently taking part in another clinical trial at the same time
  • People who are unable or unwilling to sign a written consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xing Xie, Women's Hospital, Zhejiang University School of Medicine

Phone: 008657189992206

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Registry
ClinicalTrials.gov
Start date
24 December 2018
Est. completion
1 September 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

chemotherapy cycles; hCG declined to normal spontaneously of group B

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov